Actuate Therapeutics, Inc. Operating Expenses
Actuate Therapeutics, Inc. (ACTU) reported Operating Expenses of $4.91 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Actuate Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $4.91M, a 17.80% decline year-over-year.
- Actuate Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $5.71M, a 10.36% decline year-over-year.
- Actuate Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $4.69M, a 28.52% decline year-over-year.
- Actuate Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $5.47M, a 1.47% increase year-over-year.
- Actuate Therapeutics, Inc. operating expenses for fiscal 2025 was $22.50M, a 10.59% decline from fiscal 2024.
- Actuate Therapeutics, Inc. operating expenses for fiscal 2024 was $25.16M, a 0.75% increase from fiscal 2023.
- Actuate Therapeutics, Inc. operating expenses for fiscal 2023 was $24.97M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.91M 10-Q · filed 2026-08-14 | $10.61M 10-Q · filed 2026-08-14 | $15.30M derived: sum of 3 quarters · filed 2026-08-14 | $20.77M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $5.71M 10-Q · filed 2026-05-14 | $10.39M derived: sum of 2 quarters · filed 2026-05-14 | $15.87M derived: sum of 3 quarters · filed 2026-05-14 | $21.84M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $4.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $10.16M derived: sum of 2 quarters · filed 2026-03-26 | $16.13M derived: sum of 3 quarters · filed 2026-08-14 | $22.50M 10-K · filed 2026-03-26 |
| 2025-09-30 | $5.47M 10-Q · filed 2025-11-13 | $11.44M derived: sum of 2 quarters · filed 2026-08-14 | $17.81M 10-Q · filed 2025-11-13 | $24.37M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $5.97M 10-Q · filed 2026-08-14 | $12.33M 10-Q · filed 2026-08-14 | $18.89M derived: sum of 3 quarters · filed 2026-08-14 | $24.29M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $6.37M 10-Q · filed 2026-05-14 | $12.92M derived: sum of 2 quarters · filed 2026-05-14 | $18.32M derived: sum of 3 quarters · filed 2026-05-14 | $23.75M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $6.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $11.95M derived: sum of 2 quarters · filed 2026-03-26 | $17.39M derived: sum of 3 quarters · filed 2026-03-26 | $25.16M 10-K · filed 2026-03-26 |
| 2024-09-30 | $5.39M 10-Q · filed 2025-11-13 | $10.83M derived: sum of 2 quarters · filed 2025-11-13 | $18.60M 10-Q · filed 2025-11-13 | $26.22M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $5.44M 10-Q · filed 2025-08-14 | $13.21M 10-Q · filed 2025-08-14 | $20.82M derived: sum of 3 quarters · filed 2025-08-14 | $27.30M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $7.77M 10-Q · filed 2025-05-15 | $15.39M derived: sum of 2 quarters · filed 2025-05-15 | $21.86M derived: sum of 3 quarters · filed 2025-05-15 | $27.45M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $7.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $14.09M derived: sum of 2 quarters · filed 2025-03-13 | $19.68M derived: sum of 3 quarters · filed 2025-03-13 | $24.97M 10-K · filed 2025-03-13 |
| 2023-09-30 | $6.48M 10-Q · filed 2024-11-13 | $12.06M derived: sum of 2 quarters · filed 2024-11-13 | $17.36M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $5.58M 10-Q · filed 2024-09-24 | $10.88M 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |